Showing results (201-210 of 650) with videos related to
Sort By:
Pageof 65
Nature Cancer|February 22, 2022
Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targetingRan Salomon, Hagar Rotem, Yonatan Katzenelenbogen, et al.Nature Cancer|February 28, 2022
A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncologyKatrin P Guillen, Maihi Fujita, Andrew J Butterfield, et al.Nature Cancer|February 4, 2022
A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinomaAkimasa Hayashi, Jun Fan, Ruoyao Chen, et al.Nature Cancer|February 4, 2022
The present and future of PI3K inhibitors for cancer therapyPau Castel, Eneda Toska, Jeffrey A Engelman, et al.Nature Cancer|October 18, 2021
Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease and association with anticancer therapyAstha Thakkar, Kith Pradhan, Shawn Jindal, et al.Nature Cancer|February 5, 2022
Higher prevalence of homologous recombination deficiency in tumors from African Americans versus European AmericansSanju Sinha, Khadijah A Mitchell, Adriana Zingone, et al.Nature Cancer|February 5, 2022
Negative trade-off between neoantigen repertoire breadth and the specificity of HLA-I molecules shapes antitumor immunityMáté Manczinger, Balázs Koncz, Gergő Mihály Balogh, et al.Nature Cancer|February 5, 2022
Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilitiesYosuke Tanaka, Fumiko Chiwaki, Shinya Kojima, et al.Nature Cancer|February 5, 2022
Moving pan-cancer studies from basic research toward the clinicFeng Chen, Michael C Wendl, Matthew A Wyczalkowski, et al.Nature Cancer|February 5, 2022
IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapyAdi Jacob Berger, Elinor Gigi, Lana Kupershmidt, et al.Pageof 65